Ongoing Treatment Studies

Immune Globulin Intravenous (IGIV)

Immune Globulin Intravenous (IGIV) has been approved and used for over 20 years to treat many autoimmune and immunodeficiency diseases. Because it contains anti-amyloid antibodies IgIV is being studied as a treatment for Alzheimer's disease.

Two previous small studies showed statistical improvement in cognition while reducing amyloid levels in the brain, thought to contribute to AD development. The double-blind, placebo-controlled study, called the GAP Study is further examining the safety, effectiveness and tolerabilityof IgIV in mild to moderate AD patients. GAP is recruiting 360 participants at approximately 38 sites nationwide. The study will last a maximum of 82 weeks. Two-thirds of participants will receive IgIV and one-third will get placebo.

Volunteers should have been diagnosed with probable mild to moderate Alzheimer's disease, have a study partner in contact with the participant 10 hours/week or more. As with all studies there are some things that would prevent participation including ongoing use of anti-inflammatory drugs more than 3 times weekly, having received IgIV in the past, or being treated for another serious medical illness.

Participants will be treated intravenously every two weeks for 18 months. The first three infusions will occur at USC and the rest at the participants' homes.

Rivastigmine Patch ACTION study for severe AD
CitAD trial for agitation.